Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
i decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
i decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
421
-
422
S1 File -
Published 2024“…Repeated measurements analysis showed a significant decrease in variability of the LV- and RV-GLS score differences between the expert and trainees over time (<i>p</i><sub>adj</sub><0.001), which was not significantly different between trainees. …”
-
423
S1 File -
Published 2024“…Compared with the GA group, the VAS scores at 6 hours, 12 hours, and 24 hours after surgery in the TAP+GA group were significantly decreased, and the intraoperative consumption of remifentanil and the numbers of postoperative analgesic pump presses were significantly reduced (<i>P</i><0.05). …”
-
424
Analyze data.
Published 2025“…Compared with the Sham surgery group, there was a significant decrease in NeuN over time (P < 0.01) and a significant increase in IBA-1 and CIRBP (P < 0.01) in the severe injury group. …”
-
425
Mouse spinal cord injury strike parame.
Published 2025“…Compared with the Sham surgery group, there was a significant decrease in NeuN over time (P < 0.01) and a significant increase in IBA-1 and CIRBP (P < 0.01) in the severe injury group. …”
-
426
-
427
-
428
-
429
-
430
The mean and standard deviation of parameters.
Published 2024“…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …”
-
431
The ANCOVA and Post_hoc results.
Published 2024“…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …”
-
432
CONSORT flowchart.
Published 2024“…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …”
-
433
Time to stabilization in the vertical direction.
Published 2024“…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …”
-
434
The description of games.
Published 2024“…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …”
-
435
The description of balance training.
Published 2024“…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …”
-
436
A summary of calibration standards (n = 3).
Published 2025“…<div><p>Purpose</p><p>Statins are the most commonly used drugs worldwide. Besides a significant decrease in cardiovascular diseases (CVDs) risk, the use of statins is also connected with a broad beneficial pleiotropic effect. …”
-
437
-
438
-
439
-
440